Get the Weekly Intelligence Brief — top committee picks every Sunday.

CORT vs PEN

Corcept Therapeutics Incorporated vs Penumbra, Inc. — AI-powered side-by-side comparison
CORT
Corcept Therapeutics Incorporated
56
Watch
VS
PEN
Penumbra, Inc.
67
Buy
MetricCORTPEN
AI Score 56 67
Price $111.83 $326.07
P/E Ratio 215.12× 79.78×
ROE 15.4% 12.4%
Revenue Growth YoY
Gross Margin 98.3% 67.8%
Debt / Equity 0.01× 0.14×
Dividend Yield 0.0% 0.0%
RSI (14) 61.4 79.6
Beta 0.455 0.701
Expected Upside +6.3%

AI Committee View

Current Innellis committee reasoning for CORT versus PEN.
PEN leads by 11 points.

PEN scores 67/100 (Buy) versus CORT at 56/100 (Watch).

CORT Committee View
67% agreement
6 analysts

The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Value Analyst remains cautious — p/e of 223.5 is expensive by classic value standards. This disagreement is itself the signal — the setup is not clean in either direction.

Bull Case
  • Price structure making higher highs and higher lows — Technical
  • MACD histogram positive -- bullish momentum — Technical
  • Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
  • P/E of 223.5 is expensive by classic value standards — Value
  • Price-to-book of 11.4x prices in significant intangible value — Value
  • EPS declining -62.5% YoY despite any revenue growth — Growth
PEN Committee View
80% agreement
5 analysts

The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is 2 consecutive earnings misses -- execution concerns. The committee is constructive but not yet at full conviction.

Bull Case
  • Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
  • Price structure making higher highs and higher lows — Technical
  • MACD histogram positive -- bullish momentum — Technical
Bear Case
  • 2 consecutive earnings misses -- execution concerns — Growth
  • RSI at 80 is in overbought territory — Technical
Want the full breakdown?
Committee votes, technicals, and trade plans for both companies.
CORT Full Analysis PEN Full Analysis